Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy.
作者信息
McGurk Kathryn A, Bilgehan Nagme, Ware James S
机构信息
National Heart and Lung Institute and MRC Laboratory of Medical Sciences, Imperial College London, UK (K.A.M., N.B., J.S.W.).
Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA (K.A.M., J.S.W.).
出版信息
Circulation. 2024 Jun 4;149(23):1786-1788. doi: 10.1161/CIRCULATIONAHA.123.066916. Epub 2024 Jun 3.
Abstract
摘要
相似文献
1
Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy.
Circulation. 2024 Jun 4;149(23):1786-1788. doi: 10.1161/CIRCULATIONAHA.123.066916. Epub 2024 Jun 3.
2
Mavacamten decreases maximal force and Ca sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.
Am J Physiol Heart Circ Physiol. 2021 Feb 1;320(2):H881-H890. doi: 10.1152/ajpheart.00345.2020. Epub 2020 Dec 18.
3
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.
4
Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.
Mayo Clin Proc. 2024 Feb;99(2):341-343. doi: 10.1016/j.mayocp.2023.11.019.
5
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
6
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
JACC Heart Fail. 2024 Mar;12(3):567-579. doi: 10.1016/j.jchf.2023.07.030. Epub 2023 Oct 18.
7
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
8
Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy.
J Manag Care Spec Pharm. 2022 Mar;28(3):376-378. doi: 10.18553/jmcp.2022.28.3.376.
9
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.
Clin Nurse Spec. 2024;38(3):E3. doi: 10.1097/NUR.0000000000000822.
10
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.
Clin Nurse Spec. 2024;38(3):119-121. doi: 10.1097/NUR.0000000000000821.
引用本文的文献
1
Efficacy of Mavacamten in Reducing Cardiac Obstruction in an Elderly Patient with Hypertrophic Cardiomyopathy: A Case Study.
Am J Case Rep. 2025 Apr 18;26:e946956. doi: 10.12659/AJCR.946956.
2
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.
Clin Pharmacol Ther. 2025 Feb;117(2):387-397. doi: 10.1002/cpt.3502. Epub 2024 Nov 25.
本文引用的文献
1
Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
JAMA Cardiol. 2023 Oct 1;8(10):957-965. doi: 10.1001/jamacardio.2023.3030.
2
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
3
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
4
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
Ann Intern Med. 2019 Jun 4;170(11):741-748. doi: 10.7326/M18-3016. Epub 2019 Apr 30.
5
In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin.
Xenobiotica. 2019 Jun;49(6):718-733. doi: 10.1080/00498254.2018.1495856. Epub 2018 Oct 1.
Zotero 插件